Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
The company has released a report revealing how clinical trial professionals are handling start-up, before and after COVID-19 first impacted the industry.
A leader from the clinical trial patient engagement specialist discusses how clinical trial teams can tackle tricky travel issues in the face of the pandemic.
A leader from the scientific software provider discusses the most challenging obstacles in the pharma supply chain, and solutions that can conquer them.
An executive from Pharmaceutical Associates Inc. believes bringing drug manufacturing back to the country will help avoid shortages and other disasters.
A leader from the specialty logistics firm discusses how the clinical researching industry is shifting, thanks in large part to the pandemic, and how to prepare for the future.
The company’s Sandoz division is offering 15 generic and OTC medicines to be sold at zero profit to low- and middle-income countries to treat the virus.
A leader with the health data specialists looks at how COVID-19 has impacted the clinical research industry, and what the future of the field might look like.
A leader from the healthcare solutions firm shares perspective on how application of advanced technologies has driven the evolution of the entire industry.
The agency continues to offer advice to pharma industry professionals during the global public health crisis, and offer advice on developing solutions.
The clinical trial site network company's survey of participants offers information that could shed light on ways to improve recruitment and retention.
The two companies will work together to promote technology for at-home clinical research conducted in trials focused on developing respiratory therapies.
After receiving FDA approval, the pharmaceutical company has announced plans to launch a Phase I trial for an inhaled version of the COVID-19 treatment.
The CDMO has landed a grant from the Bill and Melinda Gates Foundation’s COVID-19 Therapeutics Accelerator for clinical research in the sub-Saharan region.
The federal agency continues to aid drug developers, trial teams and the public with advice and actions related to the virus behind the global pandemic.
